Illumina Inc
NASDAQ:ILMN
Illumina Inc
Cash from Operating Activities
Illumina Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Illumina Inc
NASDAQ:ILMN
|
Cash from Operating Activities
$837m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
5%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
|
Danaher Corp
NYSE:DHR
|
Cash from Operating Activities
$6.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash from Operating Activities
$968.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Operating Activities
$1.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
3%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Operating Activities
$2.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
|
Illumina Inc
Glance View
In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.
See Also
What is Illumina Inc's Cash from Operating Activities?
Cash from Operating Activities
837m
USD
Based on the financial report for Dec 29, 2024, Illumina Inc's Cash from Operating Activities amounts to 837m USD.
What is Illumina Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
5%
Over the last year, the Cash from Operating Activities growth was 75%. The average annual Cash from Operating Activities growth rates for Illumina Inc have been 15% over the past three years , -4% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet